DXCMDexcom
Is it growing?
Growing: revenue growing +16% year on year, earnings up +75% year on year, and operating margin widening (+7.0 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +18% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 22.9% now against 15.9% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is DXCM growing?
Dexcom has grown revenue 16% a year over three years and 18% a year over five, with earnings per share compounding at 43%.
Revenue growth, 3-year annual rate · Medical Devices median +12% · compounding fast · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +18%
Revenue growth, 5-year rate · +16% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +43%
Earnings per share, 3-year rate · revenue +16% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $2.45B
- Revenue FY2022
- $2.91B
- Revenue FY2023
- $3.62B
- Revenue FY2024
- $4.03B
- Revenue FY2025
- $4.66B
Annual income statements as filed with the SEC.
Medical Devices
The closest names by size in the same industry